{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-024913","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2026-05-22T12:00:37+00:00","discovered_at":"2026-05-22T12:05:00.508873+00:00","generated_at":"2026-05-22T12:09:06.668846+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GT Biopharma receives Nasdaq extension to Nov 16, 2026 to meet $1 minimum bid price","bullets":["Received Nasdaq Staff letter on May 20, 2026 granting 180-day extension until Nov 16, 2026 for minimum bid price compliance.","Previously received initial deficiency notice on Nov 20, 2025; initial 180-day period expired May 19, 2026.","Company meets all other Nasdaq Capital Market initial listing requirements except for minimum bid price.","No assurance of compliance; company will monitor bid price and assess options to regain compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-024913","json":"https://secwatch.observer/filing/0001493152-26-024913.json","markdown":"https://secwatch.observer/filing/0001493152-26-024913.md","text":"https://secwatch.observer/filing/0001493152-26-024913.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/0001493152-26-024913-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T12:09:06.668846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f3e91a8366d603256662576fcb1ae6f193640bd2","claim":"GT Biopharma, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(H)).","evidence_excerpt":"May 20, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), received a letter from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/0001493152-26-024913-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001193125-26-251421","ticker":"GENC","company_name":"GENCOR INDUSTRIES INC","filed_at":"2026-06-01T20:09:26+00:00","headline":"Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251421","json":"https://secwatch.observer/filing/0001193125-26-251421.json","markdown":"https://secwatch.observer/filing/0001193125-26-251421.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/d135716d8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"May 20, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), received a letter from the Nasdaq Listing Qualifications\nStaff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/0001493152-26-024913-index.htm","comparable_excerpt":"May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm"}},{"accession":"0001683168-26-004399","ticker":"CSAI","company_name":"CLOUDASTRUCTURE, INC.","filed_at":"2026-05-29T21:09:11+00:00","headline":"Cloudastructure receives Nasdaq delinquency notice for late Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004399","json":"https://secwatch.observer/filing/0001683168-26-004399.json","markdown":"https://secwatch.observer/filing/0001683168-26-004399.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/0001683168-26-004399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/cloud_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"May 20, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), received a letter from the Nasdaq Listing Qualifications\nStaff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/0001493152-26-024913-index.htm","comparable_excerpt":"May 26, 2026, Cloudastructure,\nInc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq\nStock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for\nthe period ended March 31, 2026 (“Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which\nrequires timely filing of all required periodic financial reports with the Securities and Exchange Commission. The Company requires additional\ntime to review and confirm the accounting treatment for its outstand","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/0001683168-26-004399-index.htm"}},{"accession":"0001193805-26-000723","ticker":"GURE","company_name":"GULF RESOURCES, INC.","filed_at":"2026-05-29T20:45:30+00:00","headline":"Gulf Resources receives Nasdaq delisting notice for late Q1 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-000723","json":"https://secwatch.observer/filing/0001193805-26-000723.json","markdown":"https://secwatch.observer/filing/0001193805-26-000723.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/0001193805-26-000723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/e665526_8k-gulfresources.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"May 20, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), received a letter from the Nasdaq Listing Qualifications\nStaff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/0001493152-26-024913-index.htm","comparable_excerpt":"May 26, 2026, Gulf Resources\n(the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq\nStock Market LLC (“Nasdaq”), indicating that, as a result of not having timely filed its quarterly report on Form 10-Q for\nthe quarter ended March 31, 2026 (the “Form 10-Q”), and the Company remains delinquent in filing its annual report on Form\n10-K for the year ended December 31, 2025 (the “Initial Delinquent Filing”), the Company is in non-compliance with Nasdaq\nListing Rule 5250(c)(1), which requires timely filing all required periodic financial reports wit","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/0001193805-26-000723-index.htm"}},{"accession":"0001628280-26-039190","ticker":"FTHM","company_name":"Fathom Holdings Inc.","filed_at":"2026-05-29T20:15:13+00:00","headline":"Fathom Holdings receives Nasdaq notice for late Q1 2026 10-Q filing; 60 days to submit plan","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039190","json":"https://secwatch.observer/filing/0001628280-26-039190.json","markdown":"https://secwatch.observer/filing/0001628280-26-039190.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1753162/000162828026039190/0001628280-26-039190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1753162/000162828026039190/fthm-20260522.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"May 20, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), received a letter from the Nasdaq Listing Qualifications\nStaff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/0001493152-26-024913-index.htm","comparable_excerpt":"May 22, 2026, Fathom Holdings Inc. (the “Company”) received a notification letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission (the “Filing Requirement”). In accordance with Nasdaq’s listing rules, the Company has 60 calendar days from the date of the notification letter","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1753162/000162828026039190/0001628280-26-039190-index.htm"}},{"accession":"0001493152-26-025629","ticker":"CDT","company_name":"CDT Equity Inc.","filed_at":"2026-05-28T20:30:30+00:00","headline":"CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025629","json":"https://secwatch.observer/filing/0001493152-26-025629.json","markdown":"https://secwatch.observer/filing/0001493152-26-025629.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/0001493152-26-025629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"May 20, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), received a letter from the Nasdaq Listing Qualifications\nStaff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/0001493152-26-024913-index.htm","comparable_excerpt":"May 21, 2026, CDT Equity Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Nasdaq Listing\nQualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with\nNasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”) because the Company did not file its Quarterly Report\non Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”) in a timely manner, as required for continued\nlisting on The Nasdaq Capital Market. The Notice has no immediate effect on the listing or trading of the Company’s","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/0001493152-26-025629-index.htm"}},{"accession":"0001493152-26-025454","ticker":"GWAV","company_name":"Greenwave Technology Solutions, Inc.","filed_at":"2026-05-27T21:25:20+00:00","headline":"Greenwave receives second Nasdaq delinquency notice for late Q1 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025454","json":"https://secwatch.observer/filing/0001493152-26-025454.json","markdown":"https://secwatch.observer/filing/0001493152-26-025454.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589149/000149315226025454/0001493152-26-025454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589149/000149315226025454/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"May 20, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), received a letter from the Nasdaq Listing Qualifications\nStaff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/0001493152-26-024913-index.htm","comparable_excerpt":"May 21, 2026, the Company received an additional delinquency notification letter (the “Notice”) from Nasdaq due to the Company’s\nfailure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1589149/000149315226025454/0001493152-26-025454-index.htm"}},{"accession":"0001213900-26-061545","ticker":"CHAR","company_name":"Charlton Aria Acquisition Corp","filed_at":"2026-05-27T20:41:44+00:00","headline":"Charlton Aria receives Nasdaq delinquency notice for untimely Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-061545","json":"https://secwatch.observer/filing/0001213900-26-061545.json","markdown":"https://secwatch.observer/filing/0001213900-26-061545.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2024459/000121390026061545/0001213900-26-061545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2024459/000121390026061545/ea0292193-8k_charlton.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"May 20, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), received a letter from the Nasdaq Listing Qualifications\nStaff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/0001493152-26-024913-index.htm","comparable_excerpt":"May 22, 2026, Charlton\nAria Acquisition Corporation (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2024459/000121390026061545/0001213900-26-061545-index.htm"}},{"accession":"0001213900-26-061511","ticker":"BRLS","company_name":"Borealis Foods Inc.","filed_at":"2026-05-27T20:15:20+00:00","headline":"Borealis Foods receives Nasdaq deficiency notice for delayed Q1 2026 10-Q; supplements prior 2025 10-K notice","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-061511","json":"https://secwatch.observer/filing/0001213900-26-061511.json","markdown":"https://secwatch.observer/filing/0001213900-26-061511.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1852973/000121390026061511/0001213900-26-061511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1852973/000121390026061511/ea0292244-8k_borealis.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"May 20, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), received a letter from the Nasdaq Listing Qualifications\nStaff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/0001493152-26-024913-index.htm","comparable_excerpt":"May 21, 2026, a notice\n(the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, because the\nCompany has not yet filed the Q12026 Form 10-Q, the Company no longer complies with Nasdaq Lis","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1852973/000121390026061511/0001213900-26-061511-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}